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Objectives: Positivity of both immumoglobulin A anti-tissue transglutami-
nase (TTG) and anti-endomysium antibodies (EMA) has a positive
predictive value of nearly 100% for celiac disease (CD). The objective
of the present study was to evaluate whether patients of any age, with high
pretest probability of CD and high titre of anti-TTG and EMA positivity,
have a high probability of intestinal damage and may not require the biopsy
for final diagnosis.
Methods: A retrospective analysis of 412 consecutively referred patients,
age range 10 months to 72 years, who underwent small-bowel biopsy for
suspicion of CD and positivity to both anti-TTG and EMA, was performed at
4 Italian centers. Biopsies were evaluated independently by 2 pathologists
using Marsh modified classification; in cases of dissimilar results, a third
pathologist examined the biopsy. The final histological finding diagnosis
was expressed as the prevalent or highest score assigned by the pathologist
board.
Results: Three hundred ninety-six patients (96.1%) had histological
findings consistent with CD (grade 2 and 3a, 3b, or 3c of modified
Marsh classification). An anti-TTG ratio 7 was able to identify with
the 3 assays used (Celikey, anti-TTG immumoglobulin A, EuTTG) all of
the patients with significant mucosal damage (Marsh2) independent of age
and sex; specificity and positive predictive value were 100%. An anti-TTG
ratio >20 was more specific (99.8%) for identification of patients with
villous atrophy (Marsh 3 a, b, or c).
Conclusions: Patients with positivity of anti-TTG7-fold cutoff, confirmed ESPGHAN and NASPGHAN. Un
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(JPGN 2012;55: 44–49)C eliac disease (CD) is an immune-mediated enteropathycaused by a permanent sensitivity to gluten in genetically
susceptible individuals (1). First considered a rare malabsorption
syndrome of childhood, CD is now recognized as a common
condition that may be diagnosed at any age and that affects many
organs and systems.
Clinical manifestations of CD vary greatly according to the
extension and duration of disease, and to the age of the patient (2).
Diagnosis of CD is based on a combination of clinical findings,
positivity of serological tests, and histological demonstration of
duodenal mucosal damage.
The anti-tissue transglutaminase (TTG) antibody assay is
actually identified as the best test to screen patients with suspected
CD. Anti-TTG assays using recombinant antigen show a high
sensitivity compared with anti-endomysium antibodies (EMA)
and a good positive predictive value (PPV); although an inter-
national standard was not available, systematic reviews have
concluded that anti-TTG assay is the test with a better diagnostic
performance for identifying CD in adults and in children older than
2 years (3–6).
The use of the EMA assay in daily practice is limited by high
costs and subjective interpretation with unacceptable variability
among laboratories that perform this test (6); however, because of
its high specificity it is actually proposed in diagnostic protocols
to confirm a positive result of anti-TTG antibody assay. A positivity
of both anti-TTG antibody assay and EMA has a sensitivity and
a PVV for CD of almost 100% (7).
In the 1990s, the European Society of Pediatric Gastro-
enterology, Hepatology, and Nutrition proposed a revised CD diag-
nostic protocol. Based on these revised criteria, if the anamnesis,
the clinical history, and the screening results are suggestive of the
disease, a single intestinal biopsy followed by a favorable response
to a gluten-free diet (GFD) is sufficient to confirm the diagnosis of
CD (8). Although biopsy is actually considered the criterion standard
for the diagnosis of CD, it has many limitations. The possible patchy
distribution of the intestinal mucosal damage, and the incorrect
orientation of the biopsy for appropriate evaluation of the villous
morphology, limits the value of the biopsy (6,9,10).authorized reproduction of this article is prohibited.
Complete villous atrophy is typical of CD, but it is now
considered the extreme end of a continuous spectrum of tissue
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Codamage that can be detected during the acute phase of the disease.
In fact, according to the Marsh classification modified by
Oberhuber (11,12) the presence of an inflammatory infiltrate of
CD3 lymphocytes >25 of 100 enterocytes (Marsh 1) alone or
associated with hyperplasia of the crypts (Marsh 2) can be related
to CD in the presence of symptoms and serology suggestive of
disease (13); however, there is poor agreement among different
pathologists in evaluating the entity of intestinal damage, particu-
larly when it is minimal (14). Given the high performance of
the screening test available and the limits of the duodenal biopsy,
some authors proposed a modification of the diagnostic algorithm
for CD, providing the possibility of not resorting to biopsy in
presence of high levels of TTG (15–18).
The aim of the present study was to evaluate whether, in
patients with high pretest probability of disease, the positivity of
both anti-TTG and EMA is associated in a high percentage of cases
with significant duodenal damage (Marsh 2), also in the presence
of a small level of anti-TTG antibodies and independent of the assay
used; this finding would make unnecessary the use of biopsy in
carefully selected cases.
METHODS
Four hundred twelve consecutively investigated patients (134
males and 278 females; 249 age 12 years or younger; age range
10 months–72 years; mean age 17.41þ 16.83, median 10 years)
selected during 2006–2007 at 4 Italian centers (Riuniti Hospital,
Bergamo; Buccheri-La Ferla Hospital, Palermo; Santa Maria degli
Angeli Hospital, Pordenone; and S. Maria della Misericordia
Hospital, Udine) were included. The patients had to respond
simultaneously to the following criteria: suggestive symptoms
for CD and/or risk factors, positivity to both anti-TTG antibodies
and EMA, availability of hematoxylin/eosin-stained histological
specimens, and immunohistochemistry for CD3.
Twenty-five patients (6% of total: 14 adults and 11 age
12 years and younger) did not have any symptoms and were
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investigated because of risk factors only. Comorbid conditions
and symptoms of enrolled patients are shown in Table 1. The
TABLE 1. Distribution of presenting symptoms and risk factors in
C
Symptom
Abdominal (pain, diarrhea, distension)
Failure to thrive
Short stature only
Weight loss only
Iron deficiency anemia
Constipation
Vomiting
Unexplained elevation of transaminases
Folate deficiency
Osteoporosis
Delayed puberty
Risk factor
Celiac disease in a first-degree relative
Autoimmune thyroid disease
Type 1 diabetes mellitus
Sjogren syndrome
Primary biliary cirrhosis
Down syndrome

Younger than 12 years.
www.jpgn.orgserological tests performed at the participating centers immediately
before biopsy were considered. Patients with contradictory sero-
logical tests (12 cases, all with low anti-TTG antibody level and
EMA negative) or with immunoglobulin A (IgA) deficiency and
patients receiving GFD or suspected of having started the diet
before the histological evaluation were not included. Overall,
selected patients represent approximately 70% of those who yearly
undergo a biopsy for suspected CD at the 4 centers.
Serological Data
Serum anti-TTG antibodies and EMA were measured by
the commercial enzyme-linked immunosorbent assays and indirect
immunofluorescence tests conducted routinely at each center.
Serum anti-TTG antibodies were measured using assays with
human recombinant TTG as antigen. In particular, the following
assays were used in the study: Celikey, Phadia GmbH, Freiburg,
Germany (PH, 3 centers, 330 patients); anti-TTG IgA, Orgentec
Diagnostika GmbH, Mainz, Germany (OR, 2 centers, 42 patients);
and EuTTG, Eurospital, Trieste, Italy (EU, 1 center, 40 patients).
Two centers changed the kits during the study period. The results
were expressed in units per milliliter. A decisional cutoff calculated
at the 95% confidence interval by a receiver operating curve, as
described by Van Meensel et al (19), was used for each assay;
consequently, we considered all of the samples with values
greater than the following cutoff to be positive: PH 2.64U/mL;
EU 3.69U/mL, OR 9.73U/mL.
To compare results obtained with different kits, because
of lack of an internationally accepted standard method, results
were expressed also as anti-TTG ratio; that is, the ratio between
the value obtained for the single patient and the decisional cutoff,
as previously described (18).
EMA were detected on cryostat sections of monkey eso-
phagus at a starting dilution of 1:10, and the results were expressed
as positive or negative. The commercial indirect immunofluore-
IgA TTG Antibody Ratio and Histological Finding in CDauthorized reproduction of this article is prohibited.
scence used by the participating centers were manufactured by
INOVA, San Diego, CA (2 centers, 351 patients); Euroimmun,
adults and children
hildren, n¼ 249 (%) Adults, n¼ 163 (%)
196 (79) 65 (40)
27 (11) 0
12 (5) 0
15 (6) 8 (5)
40 (16) 80 (49)
7 (3) 5 (3)
10 (4) 2 (1)
6 (2.4) 45 (28)
0 3 (2)
0 7 (4)
0 5 (3)
30 (12) 15 (9)
17 (7) 29 (18)
7 (3) 5 (3)
0 3 (2)
0 2 (1)
5 (2) 0
45
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TABLE 2. Histological evaluation in 408 selected patients
Histology No. patients (% total)
Marsh 0 6 (1.5)
Marsh 1 6 (1.5)
Marsh 2 12 (2.9)
Marsh 3 384 (94.1)
3a 39 (10.2)
3b 123 (32.0)
3c 222 (57.8)
Total 408 (100)
JPGN  Volume 55, Number 1, July 2012Lubeck, Germany (1 center, 40 patients); and Eurospital, Trieste,
Italy (1 center, 21 patients). All of the centers involved in the study
participated in the United Kingdom External Quality Assessment
Scheme and in the Italian Biomedical Research Centre External
Quality Program for celiac serology.
Histological Evaluation
Histological slides, obtained from multiple endoscopic
biopsies of the distal portion of duodenum collected by esophago-
gastroduodenoscopy (EGD) and evaluated by the pathologist at the
participating centers during the first evaluation of the patients,
were reviewed by a second blinded expert pathologist; the histo-
logical lesions were classified according to Oberhuber-modified
Marsh classification (12). All of the biopsies were performed by
forceps. For each case hematoxylin-eosin- and CD3-stained slides
were available; CD3 staining was routinely performed in cases of
suspected celiac disease.
A third pathologist was involved in revision if results
were not concordant (ie, 1 Marsh grade) and, if the specimen
resulted in different diagnosis by the pathologist team, the prevalent
score assigned by the pathologist board was considered for final
diagnosis. A modified Marsh grade 2 was considered suggestive
of the presence of CD.
Statistical Analysis
For statistical analysis, histological diagnoses were scored
as Marsh 0, 1, and 2, whereas scores>3 (3a, 3b, 3c) were converted
to an ordinal scale of 3, 4, and 5, respectively. Spearman
rank correlation and logistic regression were used to evaluate the
association between Marsh scores and anti-TTG ratio.
RESULTS
A total of 412 patients were included in the study. In
4 patients (0.9% of total), the specimen was found inadequate
for diagnosis, due to insufficient sample, and was excluded from
the study. As far as the remaining 408 patients, 246 (66.4%) were
ages 12 years and younger; the ratio between girls (n¼ 275) and
boys (n¼ 133) was 2.07, representative of the distribution of CD
in the general population (20). The ratio between each anti-TTG
antibody value and the corresponding decisional cutoff ranged
between 1.01 and >38.26.
The results of the histological findings on biopsy obtained by
EGD are shown in Table 2. Sixty-six of 408 samples (16%) received
a different histological classification given by 2 pathologists.
In particular, a different grade of villous atrophy (Marsh 3a, b,
or c) was assigned to 42 samples (10.2%) and the highest score was
recorded; 24 of 408 (5.8%) of the total specimens collected received
a Marsh classification–based diagnosis with at least 1 grade of
difference and underwent a review by a third pathologist. Regarding
the classification received at the time of diagnosis, 12 were
reallocated to a higher degree, 8 to a lower degree, and in 4 cases,
the samples were considered inadequate; however, the degree of
correlation between the pathologists was satisfactory.
Twelve of 408 samples (2.9%) had histology poorly
consistent with CD: 6 had normal villous morphology and 6 showed
only an increase in intraepithelial lymphocytes (CD3 >25/100
enterocytes) without atrophy and were classified as Marsh type
1; anti-TTG antibodies of these 12 patients ranged between 5.11 and
16.6 U/mL and the anti-TTG ratio ranged between 1.04 and 6.29.
Of these 12 patients, 8 had a final diagnosis of CD: 4 patients
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were classified as having CD at 1 reference center on the basis of
serological data, presence of human leukocyte antigen (HLA) of
46susceptibility, suggestive symptoms and their disappearance, and
negativity of serology after GFD. They showed a suggestive biopsy
(Marsh 2) at the first histological evaluation, but afterward were
classified as Marsh 0 (3 patients) and Marsh 1 (1 patient) by the
pathologist board. Another 4 patients, all with Marsh 1, had risk
factors (2 with autoimmune thyroid disease, 1 with Down syn-
drome, and 1 with 2 first-degree relatives affected) and positivity of
serological tests at low levels. Three of these patients underwent
a second biopsy after 4 months, and Marsh 1 score has been
confirmed; 1 (Down syndrome patient) received a final diagnosis
based on increased levels of anti-TTG and anti-EMA and worsening
of symptoms, but biopsy was not repeated. Finally, 4 patients,
1 with Marsh 1 classification and 3 with normal mucosa, were lost
to follow-up.
Three hundred ninety-six of 408 specimens (97%) had a
histology compatible with CD, with inflammatory infiltrate and
hyperplasia of the crypts (Marsh 2, n¼ 12, 2.9%) or varying degrees
of villous atrophy (Marsh 3a, b, or c: n¼ 384, 94.1%). All of these
patients had a final diagnosis of CD. The correlation between anti-
TTG ratio, histological findings, and final diagnosis of CD for the
different assays used in the study is depicted in Table 3.
Independent of age, sex, and commercial kit used for
determining anti-TTG antibodies, already at a value of ratio >2,
91.6% of patients showed a mucosal atrophy (Marsh 3a, b, c), which
is greatly suggestive of CD; this percentage increased to 98.7%
when a ratio>7 was considered. A value of anti-TTG ratio>20 had
almost absolute correspondence with atrophic lesions (99.4%)
because only 1 patient showed no villous atrophy (Marsh 2). When
Marsh 2 type was also included as criteria for suggestive CD, a ratio
value >7 showed a 100% sensibility and PPV for significant
mucosal damage above this value; no patient had Marsh 0 or 1.
The PPV of anti-TTG ratio for presence of significant lesions
(Marsh 2), mucosal atrophy (Marsh 3a, b, c), and presence of
CD is shown in Table 4.
DISCUSSION
CD is now generally accepted as a much more complex
disease than previously thought, and hence a multidisciplinary
approach is often required for its correct diagnosis (21).
Although histology is considered the criterion standard
for the diagnosis of CD, its limitations have become more
apparent with the availability of even more accurate tests (HLA,
anti-TTG assay, EMA assay, anti-deamidated gliadin peptides
assay, subepithelial deposits of IgA) that have improved the
diagnostic accuracy and have emphasized the limits of histological
examination (22).
In the initial phases of the disease, CD-related mucosalauthorized reproduction of this article is prohibited.
damage and atrophy may occur discontinuously (9); therefore, at
least 4 endoscopic biopsies must be taken from different parts of the
www.jpgn.org
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TABLE 3. Correlation among anti-TTG ratio, histological findings, and final diagnosis of CD
TTG ratio Marsh 0 Marsh 1 Marsh 2 Marsh 3 Total CD
<2.0 PH 2 (2) 1z 4 4 11 9
OR 1y 0 1 2 4 4
EU 0 0 0 4 4 4
2.0–7.00 PH 3 (1) (2y) 5 (1) (1y) (3z) 1 44 53 51
OR 0 0 0 5 5 5
EU 0 0 1 34 35 35
7.00–20.00 PH 0 0 3 87 90 90
OR 0 0 1 30 31 31
EU 0 0 0 1 1 1
>20 PH 0 0 1 173 174 174
OR 0 0 0 0 0 0
EU 0 0 0 0 0 0
Total 6 6 12 384 408 404
CD (%) 3 (50) 5 (83.3) 12 (100) 384 (100) 404/408 (99)
CD¼ celiac disease; EU¼Eurospital; OR¼Orgentec; PH¼Phadia; TTG¼ anti-tissue transglutaminase antibodies.
Patients with final diagnosis unavailable.
yPatients who received diagnosis of CD at 1 reference center, based on positivity of serological tests, symptoms, and suggestive biopsy at the first histological
evaluation (Marsh 2/3) but classified as Marsh 0 or Marsh 1 by the pathologist board.
JPGN  Volume 55, Number 1, July 2012 IgA TTG Antibody Ratio and Histological Finding in CDduodenal mucosa (23). The samples must be properly positioned,
oriented, and sectioned. It is common knowledge that an incorrect
preparation of the sample can simulate both a false shortness of the
villi and an increased count of lymphocytes in epithelium and
lamina propria, with an outcome of a false diagnosis of CD
(10,24,25). In some cases, especially in extremely young children,
the amount of material collected may be insufficient to reach a
definitive diagnosis; a European multicenter study showed
that >10% of histological specimens collected for suspected CD
were insufficient for diagnosis (6). Another limiting factor of
histological examination is the interobserver variability and the
poor reproducibility among pathologists. Corazza et al (14) found
that the degree of correlation among pathologists with similar
experience did not exceed 75%, and was even lower, around
25%, for the initial grade of lesions (modified Marsh types 1
and 2), which may give rise to doubt or diagnostic errors. Finally,
in early life, EGD is generally performed under anesthesia, with
increased risk and reduced compliance of parents to subject the
child to an invasive examination.
Many studies have tried to establish a correlation between
autoantibody levels and extent of mucosal damage, with the aim
of limiting the number of endoscopies required for the diagnosis
of CD. A European multicenter study by the International
Working Group on Eu-TG showed that in children, more severe
zPatients with later diagnosis.pyright 2012 by ESPGHAN and NASPGHAN. Un
degrees of intestinal damage correspond to higher levels of anti-
TTG antibodies (26).
TABLE 4. PPV of TTG ratio for suggestive histological lesions (Ma
TTG ratio No. patients Marsh 3 (a, b, c) only
<2.0 19 10
>2.0 389 374
>5.0 333 326
>10.0 263 259
>20.0 174 173
CD¼ celiac disease; PPV¼ positive predictive value; TTG¼ anti-tissue tran
www.jpgn.orgHansson et al (27) demonstrated a correlation between anti-
TTG antibody levels and mucosal damage in a cohort of 57 children
with a final diagnosis of CD; the same results were obtained by
Tursi et al (28) in adult subjects using a guinea pig anti-TTG assay;
they also suggested a possible role for anti-TTG antibodies in
predicting mucosal damage, independent of the source of the TTG.
Scoglio et al (29) first showed the high pretest predictive
value of anti-TTG antibodies and EMA, assuming the avoidance of
intestinal biopsy to confirm a clinical suspicion of CD, but other
authors proposed finding a value of anti-TTG antibodies able to
identify a mucosal injury suggestive of CD, and, consequently, to
eliminate the need for EGD in some selected cases.
Diamanti et al (16) suggested that in patients with symptoms,
there was a strong correlation between anti-TTG antibody levels
and degree of mucosal injury, and demonstrated that a anti-TTG
cutoff value 20 U/mL (5 times the cutoff) was suitable for
predicting mucosal atrophy.
In a retrospective evaluation on 103 children who had under-
gone EGD following positive anti-TTG antibody assay, Barker et al
(15) showed that 48 of 49 patients with anti-TTG >100 U/mL
(5 times the cutoff) had histological findings of modified Marsh2,
which confirms the suspected diagnosis of CD. Sensibility
and specificity of anti-TTG >100 U/mL were 98% and 97.2%,
respectively; these results were subsequently confirmed by otherauthorized reproduction of this article is prohibited.
authors (17,18). Hill et al (18) proposed the use of the ratio between
the value of anti-TTG antibodies of the patient and the decisional
rsh >–2) and CD
PPV Marsh 2 PPV CD PPV
52.6 15 78.9 17 89.5
96.1 381 97.9 386 99.2
97.9 329 98.8 331 99.4
98.5 263 100 263 100
99.4 174 100 174 100
sglutaminase antibodies.
47
Cocutoff, instead of the absolute value, to compare results obtained
with different kits in the absence of an international standard. The
study showed that in 148 adults selected on the basis of positivity of
both anti-TTG antibodies and EMA and presence of suggestive
symptoms or risk factors, a ratio >10 was able to identify the
subjects with intestinal lesions corresponding to a Marsh 2 and
therefore suggestive for the presence of CD. All of the mentioned
authors concluded that there was the possibility not to perform EGD
in patients with high pretest probability of CD and high anti-TTG
antibody levels.
Our study shares this goal, showing that for the 3 different
anti-TTG assays evaluated, an anti-TTG ratio >7 is high enough to
identify all of the subjects with Marsh 2, even if a limitation of the
present study remains the lower number of subjects tested with OR
and EU assays in comparison with the subjects tested with PH assay.
To our knowledge, this is the first multicenter study
conducted in 4 main Italian hospitals, located in different regions
and representative of the entire Italian health system. Possible
limitations of the study should be due to the fact that patients
were selected by expert clinicians and laboratory examinations
performed by expert pathologists, so that the results of the study
could not be extended or reproduced in a less expert setting;
however, the number of patients is more than that in the previous
studies and the present study evaluated a mixed population—
pediatric and adult. Another limitation could be the retrospective
data collection, and as a consequence the exclusion of some
patients for incomplete data or sera collected at different time
points than biopsies.
We selected only patients with high pretest probability of
CD (suggestive symptoms, risk factors, comorbid conditions) and
with positivity of anti-TTG antibodies and EMA. Some clinical
conditions, such as liver disease, rheumatoid arthritis, and inflam-
matory bowel disease, can cause a falsely positive anti-TTG result
(30,31), but when both anti-TTG and EMA are positive in a
patient with suggestive symptoms and/or risk factors, the prob-
ability that the patient had CD is extremely high, almost 100% (7).
Furthermore, most Italian laboratories use the diagnostic protocol
proposed by the Autoimmunity and Allergology Study Group of
the Italian Society of Laboratory Medicine, which provides an
initial screening with a highly sensitive test (anti-TTG) confirmed,
if positive, by EMA (32).
The high specificity of EMA for CD was confirmed by the
Finnish group of Maki and Kaukinen (33). They demonstrated
that symptomatic children who are EMA positive without villous
atrophy have celiac disorders; they benefit from early treatment
with GFD, with disappearance of autoantibody and resolution of
symptoms. The authors concluded that EMA positivity could be
a sufficient criterion for CD diagnosis, despite normal mucosal
structure. Similar results were obtained by the same authors in
adults (34).
In our study, in addition to the pathologist of the recruitment
center, the biopsy of every selected patient was examined by
another gastrointestinally oriented pathologist, reducing the risk
of errors and making more reliable the most critical aspect of the
study, whose outcome is predominantly based on biopsy results.
The low number of unfit biopsies and the satisfactory
agreement between the pathologist board—only 5.8% samples with
significant differences (1 grade of Marsh classification) required
a review by a third pathologist—can be explained by the large
experience of the pathologists of participating centers and the
higher percentage of biopsy with moderate to severe mucosal
lesions (20). Biopsy remains a formidable but high-cost and
time-consuming tool, not available in all of the institutions and
Alessio et alpyright 2012 by ESPGHAN and NASPGHAN. Un
requiring a pathologist confident in gastrointestinal pathology,
particularly in cases with minimal duodenal mucosal lesions.
48A possible limitation of our study is the small number of patients
with a low degree of intestinal mucosal damage that is easily under-
estimated by a nonexperienced pathologist (Marsh 0 and 1), but it is
due to the fact that the criteria of patient selection (positivity of
serological tests and symptoms or risk factors) are associated with a
high probability of finding significant mucosal damage. Furthermore,
in many cases practitioners use caution in prescribing endoscopy in
subjects with low levels of autoantibodies, mainly in infants, and
prefer to wait and follow up with the patients.
As proposed by Hill et al (18), we expressed the results of
anti-TTG as a ratio with the cutoff value calculated at the 95%
confidence interval by a receiver operating curve (19) to compare
results obtained at different centers with different commercial kits
and instrumentation; our results are, however, similar to those of
other groups. It is interesting to note that all of the authors who
investigated the correlation between anti-TTG antibody levels
(as ratio or absolute value) and degree of intestinal lesions reached
the same conclusion: high levels of autoantibodies had strong
sensitivity, specificity, and PPV for presence of intestinal damage
consistent with CD. In this regard, it appears suggestive because,
in the works mentioned, the cutoff identified by the authors,
when expressed as an anti-TTG antibody ratio, is surprisingly
similar (>5), regardless of the population selected and the type
of test used at every center. The results and the number of patients
evaluated appear sufficiently large and consistent to seriously
consider modifying national and international guidelines (35).
Catassi and Fasano (36) suggested that the rigid and often
complicated algorithms used to classify CD are unable to cover
all of the faces of the disease, so they proposed to classify as CD all
of the subjects with at least the presence of 4 criteria on 5 (presence
of HLA-DQ2 and/or -DQ8; typical symptoms; high titre of serum
celiac disease autoantibodies, celiac enteropathy at the small bowel
biopsy and response to GFD); 3 criteria were considered sufficient
if HLA was not performed. This proposal should be discussed
and approved by the international scientific community, but it has
the advantage of being extremely flexible and includes the
possibility of excluding EGD only in selected patients evaluated
at reference centers, with presence of all other criteria, including
high level of autoantibodies and positivity of both anti-TTG and
EMA. This approach could ensure the best compliance of patients
and economic advantage for the sanitary system.
CONCLUSIONS
Our work shows that patients with suggestive symptoms and/
or risk factors for CD and positivity of both anti-TTG antibodies and
EMA have a high likelihood of having duodenal damage and a final
diagnosis of CD. Regardless of the age and sex of the subject and the
type of commercial kits used in the present study, an anti-TTG
antibody ratio >7 has 100% sensitivity, specificity, and PPV for
the presence of histological lesions Marsh 2 and diagnosis of CD.
A ratio >20 had an almost absolute (99.8%) correspondence with
atrophic lesions (Marsh 3a, b, c) and 100% PPV for CD.
The present study supports the findings of other authors, and
confirms that in selected population, high levels of autoantibodies
are correlated with a higher degree of mucosal damage and presence
of CD in almost all of the cases.
We think that it is time to modify the guidelines for the
diagnosis of CD and to adopt more flexible and simple criteria to
facilitate more rapid diagnosis and treatment.
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